Microbial chassis selection for niche-specific engineered live biotherapeutics

The human microbiota comprises a vast and diverse array of microorganisms that play critical roles in maintaining health and modulating diseases. Engineered live biotherapeutic products (eLBPs) harness genetically modified microbes to perform defined therapeutic functions within the host. A central challenge in developing effective eLBPs is the rational selection of an appropriate microbial chassis, which requires consideration of safety, genetic tractability, functional performance and the target host niche. As different body sites present distinct physiological and biochemical conditions that influence microbial survival, colonisation and activity, choosing a chassis well-adapted to the target niche is essential for therapeutic durability and sustained efficacy. This review summarises microbial chassis that have been widely employed for the gut, skin, vagina and tumour microenvironment, highlighting how their characteristics enable effective function within these niches. Strategies to improve eLBP colonisation within these niches are discussed, and emerging microbial candidates that hold promise as future eLBPs are also identified.

Authors

Institutions

Publication Details

Journal
Current Opinion in Microbiology
Published
2026-03-28
DOI
https://doi.org/10.1016/j.mib.2026.102748
Primary Topic
Cancer Research and Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Microbial chassis selection for niche-specific engineered live biotherapeutics

Matthew Wook Chang, Nikhil Aggarwal, Li Ting Lee, Dongmin Byun et al.
Current Opinion in Microbiology
Cancer Research and Treatments
article

Microbial chassis selection for niche-specific engineered live biotherapeutics

Matthew Wook Chang, Nikhil Aggarwal, Li Ting Lee, Dongmin Byun, Chenxin Zhang
article en

Abstract

The human microbiota comprises a vast and diverse array of microorganisms that play critical roles in maintaining health and modulating diseases. Engineered live biotherapeutic products (eLBPs) harness genetically modified microbes to perform defined therapeutic functions within the host. A central challenge in developing effective eLBPs is the rational selection of an appropriate microbial chassis, which requires consideration of safety, genetic tractability, functional performance and the target host niche. As different body sites present distinct physiological and biochemical conditions that influence microbial survival, colonisation and activity, choosing a chassis well-adapted to the target niche is essential for therapeutic durability and sustained efficacy. This review summarises microbial chassis that have been widely employed for the gut, skin, vagina and tumour microenvironment, highlighting how their characteristics enable effective function within these niches. Strategies to improve eLBP colonisation within these niches are discussed, and emerging microbial candidates that hold promise as future eLBPs are also identified.

Current Opinion in MicrobiologyVol. 91
National University of Singapore (SG)
Openalex Percentile: Top 4%
Cancer Research and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Microbial chassis selection for niche-specific engineered live biotherapeutics — Matthew Wook Chang, Nikhil Aggarwal, et al. · Current Opinion in Microbiology (2026) | TGRS Research Map | TGRS